In an asthmatic patient who meets rapid sequence intubation criteria, is ketamine preferred over etomidate?

Ketamine vs Etomidate for RSI in Asthmatic Patients

For an asthmatic patient requiring rapid sequence intubation, there is no clear survival benefit to choosing ketamine over etomidate, and ketamine may actually increase the risk of post-intubation hypotension. However, ketamine's theoretical bronchodilatory properties and preservation of respiratory drive make it a reasonable choice in this specific population, despite the lack of asthma-specific comparative data.

Evidence-Based Recommendation

The 2023 Society of Critical Care Medicine guidelines explicitly state there is no difference between etomidate and other induction agents (including ketamine) with respect to mortality or hemodynamic outcomes in critically ill adults undergoing RSI 1. This is a conditional recommendation based on moderate-quality evidence.

Key Mortality Data

• A Cochrane meta-analysis of 772 patients found no mortality difference between etomidate and other induction agents (OR 1.17,95% CI 0.86-1.60) 1
• The landmark 2025 RSI trial randomizing 2,365 critically ill adults found no difference in 28-day mortality: 28.1% with ketamine vs 29.1% with etomidate (risk difference -0.8%, 95% CI -4.5 to 2.9) 2
• Multiple 2025-2026 meta-analyses consistently show no survival difference 3, 4, 5, 6

Critical Hemodynamic Consideration

Ketamine significantly increases post-intubation cardiovascular collapse compared to etomidate:

• The 2025 RSI trial found cardiovascular collapse in 22.1% with ketamine vs 17.0% with etomidate (risk difference 5.1%, 95% CI 1.9-8.3) 2
• 2026 meta-analysis confirmed increased post-intubation hypotension with ketamine (OR 1.32,95% CI 1.03-1.69) 6
• Another 2025 meta-analysis showed ketamine increases hemodynamic instability (RR 1.29,95% CI 1.07-1.57) 5

This occurs because critically ill patients often have depleted catecholamine stores, negating ketamine's sympathomimetic effects 1.

Asthma-Specific Considerations

Theoretical Advantages of Ketamine in Asthma

Ketamine possesses bronchodilatory properties and preserves respiratory drive 1, 7. Older literature suggests ketamine inhibits bronchoconstriction during induction 7. However, no high-quality studies directly compare ketamine vs etomidate specifically in asthmatic patients requiring intubation.

Important Caveat

A 2026 study of intubated patients with severe asthma exacerbations receiving continuous ketamine infusion found no improvement in PCO2 (median 67.65 mm Hg before vs 64 mm Hg after), with 52.6% experiencing tachycardia and 50% experiencing hypotension 8. This challenges the presumed benefit of ketamine in severe asthma.

Clinical Algorithm for Decision-Making

Choose Etomidate (0.2-0.3 mg/kg) if:

• Patient is hemodynamically unstable (SBP < 100 mm Hg)
• Patient has sepsis or septic shock
• Patient is elderly with cardiovascular disease
• Hemodynamic stability is the priority

Choose Ketamine (1-2 mg/kg) if:

• Patient is hemodynamically stable (SBP > 100 mm Hg)
• Active bronchospasm is present and severe
• Patient is younger without significant cardiovascular disease
• You want to avoid etomidate's adrenal suppression (though this doesn't affect mortality 1)

Avoid propofol in asthmatics requiring intubation—it causes the most profound hypotension 1.

Common Pitfalls

1. Assuming ketamine is always safer in asthma: The hemodynamic instability risk may outweigh theoretical bronchodilatory benefits, especially in critically ill patients
2. Ignoring pre-intubation hemodynamics: Ketamine's sympathomimetic effects require intact catecholamine stores
3. Expecting dramatic improvement with ketamine in severe asthma: Recent data shows minimal PCO2 improvement 8
4. Forgetting adrenal suppression is clinically irrelevant: Etomidate causes adrenal suppression 3, 5, but this doesn't translate to worse mortality 1

Nuanced Interpretation

The evidence reveals a disconnect between theoretical pharmacology and clinical outcomes. While ketamine's bronchodilatory properties seem ideal for asthma, the most recent and highest-quality evidence (2025 RSI trial) shows increased cardiovascular collapse without mortality benefit 2. The 2023 SCCM guidelines appropriately acknowledge both agents are reasonable, with selection based on individual patient factors 1.

In practice, for a hemodynamically stable asthmatic, ketamine remains defensible based on its bronchodilatory properties. For any degree of hemodynamic instability, etomidate is safer.